LIraglutide and Beta-cell RepAir (LIBRA) Study

NCT01270789 · Completed

Last updated 2026-05-28

The LIBRA Study tests whether the medication liraglutide can help preserve beta-cell function in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 63 people

Who can join Ages 30–75 · all sexes

Timeline Started 2011-01 · est. completion 2014-05

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT01270789 ↗

Description as written by the study sponsor.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). We propose a double-blind, randomized controlled study comparing the effect of liraglutide (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM. This study may demonstrate an important beta-cell protective capacity of liraglutide.

Treatments tested

Liraglutide also known as Victoza Drug

Liraglutide administered as once daily sc injection
placebo Drug

placebo administered as once daily sc injection

Main thing measured	Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2)
Sponsor	Mount Sinai Hospital, Canada
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01270789 ↗